Overview

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

Status:
Completed

Trial end date:
2020-03-15

Target enrollment:

Participant gender:

Summary

Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis.

Phase:

Phase 3

Details

Lead Sponsor:

Catalyst Pharmaceuticals, Inc.

Treatments:

3,4-diaminopyridine
4-Aminopyridine
Amifampridine
Antibodies